× Business
TelecomHealthcareDigital MarketingERPRetailMedia and EntertainmentOil and GasFood and BeveragesMarketing and AdvertisingBanking and InsuranceMetals and MiningLegalComplianceCryptocurrency
Technology
Big DataCloudIT ServiceSoftwareMobileSecurityNetworkingStorageCyber SecuritySAPData AnalysisloTBio TechQuality AssuranceEducationE-commerceGaming and VFXArtificial Intelligence
Platform
Cisco DATABASE Google IBM Juniper Microsoft M2M Oracle Red hat Saas SYMANTEC
Leadership
CEO ReviewCMO ReviewCFO ReviewCompany Review
Magazines
US ASIA ARCHIVE
Startups Opinion Yearbook Readers Speak Contact Us

Cambridge’s Eight Superstars Co-Founds a New Venture with Ahren: Invests in Artificial Intelligence

siliconreview Cambridge’s Eight Superstars Co-Founds a New Venture with Ahren: Invests in Artificial Intelligence

The Cambridge scientists agreed to invest in artificial intelligence and space to brain research and genetics. The Ahren fund is expected to raise its money during the autumn since it has already pulled in more than £100m from an exterior investor fund. Ahren’s managing partner and founder Alice Newcombe-Ellis who is a Cambridge university maths and physics graduate have turned herself into a fund manager. She has managed to reel in eight of the best research leaders and entrepreneurs of science. Now the entire team is set to go on this “science partnership” keeping in mind that all of the individuals have put in their own money and are expected to do something big in the market.

Apart from these individuals, many outside investors are also part of the venture. Many wealthy US families, Aviva, and Wittington Investments have also invested their money in the project. Alice mentioned that the project is a completely different model and won’t resemble anything out there.

As of now Ahren plans on investing four overlapping fields and they are; Brain-artificial intelligence; Genetics – Biotechnology; Space – Robotics; energy and environment. The initial investment was $10 million USD from Cambridge Epigenetix which is a biotech company. As of now, everything is going well for Alice and her venture. Let us see what happens in the future.

YOU MIGHT ALSO LIKE::

ENROLL FOR UPCOMING ISSUE